Opinion|Videos|February 20, 2025
FLAURA and FLAURA2: Key Efficacy and Safety Data
Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.
Advertisement
Video content above is prompted by the following:
- Please comment on the PFS and OS data for osimertinib monotherapy vs combination therapies in FLAURA and FLAURA2.
Advertisement
Related to this article
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.
The FDA has granted priority review to subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck cancer.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
Leukocyte interleukin injection improved OS in patients with oral cancer expressing low tumor PD-L1 levels.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
FDA has granted RMAT and fast track designations to celma-cel as a frontline consolidation in large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
2
FDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL
3
Dr Hashmi on the Identification of Candidates for CAR T-Cell Therapy in Early R/R Myeloma
4
Dr Secord on Combining Mocertatug Rezetecan With Dostarlimab in Endometrial Cancer
5